|
NSABP Protocol B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy And Radiation Therapy Alone For Women With HER2-Positive Ductal Carcinoma In Situ Resected By Lumpectomy
|
This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy. Radiation therapy is the standard treatment for patients with DCIS.
|
Principal Investigator(s):
Stephen E. Karp, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kori D. Hesse.
|